Takeda gets China's approval for $62 billion Shire purchase

Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon - Copyright Kim Kyung Hoon(Reuters)

By Reuters

Published on 14/09/2018 - 09:34•Updated 26/04/2024 - 19:01

Comments

(Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T> said on Friday China's market regulator had approved its $62 billion (47 billion pounds) acquisition of Shire Plc <SHP.L>, bringing it closer to becoming a global top 10 drugmaker.

The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from regulators in the United States and Brazil.

(Reporting by Shashwat Awasthi in Bengaluru; Editing by Sai Sachin Ravikumar)

Comments

You might also like